trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Losartan, candesartan, irbesartan, olmesartan, and valsartan are classified as angiotensin II receptor blockers.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
6 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Losartan, candesartan, irbesartan, olmesartan, and valsartan are classified as angiotensin II receptor blockers?

Yes. Multiple authoritative reference sources and medical databases confirm that losartan, candesartan, irbesartan, olmesartan, and valsartan are all classified as angiotensin II receptor blockers (ARBs).

Verdict: SUPPORTED · 6 sources for, 0 against · Last checked

How claims like this are judged

Judged against reference works: claims of this kind are settled by reference works, not journal abstracts.

Evidence for · 6
Wikipedia: Losartan
Reference article covering this claim directly
Get citation
Wikipedia: Losartan. (n.d.). Wikipedia. https://en.wikipedia.org/wiki/Losartan

See more details
More for · 5
PLOS (all journals): The Effect of Renin-Angiotensin-Aldosterone System Blockade Medications on Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography: A Meta-Analysis
Lists valsartan, losartan, irbesartan, candesartan, and olmesartan as ARBs.
Get citation
PLOS (all journals): The Effect of Renin-Angiotensin-Aldosterone System Blockade Medications on Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography: A Meta-Analysis. (n.d.). PLOS (all journals). https://doi.org/10.1371/journal.pone.0129747

Agency for Healthcare Research and Quality (US): Utilization of antihypertensive drug classes among Medicare beneficiaries with hypertension, 2007 to 2009 - Data Points Publication Series
Categorizes candesartan, irbesartan, losartan, olmesartan, and valsartan as angiotensin II receptor antagonists (ARBs).
Get citation
Agency for Healthcare Research and Quality (US): Utilization of antihypertensive drug classes among Medicare beneficiaries with hypertension, 2007 to 2009 - Data Points Publication Series. (n.d.). Agency for Healthcare Research and Quality (US). https://www.ncbi.nlm.nih.gov/books/NBK63603/#dp8

Office of the Assistant Secretary for Planning and Evaluation (ASPE): ASPE Summary - ASPE Report to Congress: Impact of Drug Shortages on Consumer Costs
Lists losartan, olmesartan, irbesartan, and candesartan as substitutes for valsartan under cardiovascular drugs.
Get citation
Office of the Assistant Secretary for Planning and Evaluation (ASPE): ASPE Summary - ASPE Report to Congress: Impact of Drug Shortages on Consumer Costs. (n.d.). Office of the Assistant Secretary for Planning and Evaluation (ASPE). https://www.ncbi.nlm.nih.gov/books/NBK603205/#ch1

ClinicalTrials.gov: Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
Lists losartan, valsartan, candesartan, irbesartan, and olmesartan under ARBs.
Get citation
ClinicalTrials.gov: Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04606563

LibreTexts: LibreTexts: 18.06: Drugs for the Heart
Includes candesartan, irbesartan, losartan, and valsartan under angiotensin II receptor blockers.
Get citation
LibreTexts: LibreTexts: 18.06%3A Drugs for the Heart. (n.d.). LibreTexts. https://chem.libretexts.org/Bookshelves/Introductory_Chemistry/Chemistry_for_Changing_Times_(Hill_and_McCreary)/18%3A_Drugs/18.06%3A_Drugs_for_the_Heart

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work